Search Results
Martine Piccart: Patients with HER2 positive breast cancer
ONC-CHAT: Dr. Martine Piccart, 'Absolutely No Advantage' to 2 Years of Trastuzumab
Dr. Martine Piccart on HER2-targeted therapies in breast cancer
Martine Piccart, MD, PhD: No Benefit in Extending Herceptin in HER2 Breast Cancer
Dr. Piccart on the Success of Trastuzumab
Dr. Piccart on the Implications of the HERA Trial
Dr. Piccart on Personalized Care for Breast Cancer
Martine J. Piccart-Gebhart, et al.
Post-Op use of Herceptin, Part 1
Dr. Piccart on the Changing View of Anti-HER2 Therapies
Martine Piccart-Gebhart: Survival follow-up analysis of the NeoALTTO study (BIG 1-06)
Martine Piccart-Gebhart
